Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...

Holz also highlights that Eli Lilly's pipeline, especially in GLP-1 treatments, remains promising for long-term growth. "The GLP-1 class is the most important category by far, and they're going to ...

Global pharmaceutical company Eli Lilly's (LLY) preliminary 2024 revenue ... and they're going to have oral data for a pill, I think, sometime in the first half of this year [toward] the spring ...

Separately, Eli Lilly said that it expects its new weight loss pill to be approved by U.S. regulators in 2026. The Indianapolis, Indiana-based company said that it will release late-stage trial ...